hVIVO
40 Bank Street, Floor 24, London, England, E14 5NR, United Kingdom
Overview
hVIVO, a specialty biopharma company with clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. hVIVO changed its name from Retroscreen Virology in April 2015. The business is a plc quoted on the AIM London Stock Exchange (ticker ‘HVO’).
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Biotechnology
- Health Care
- Medical
Investment portfolio
- PrEP Biopharm
Led · Series A · Nov 2015
PrEP Biopharm is a development-stage biopharmaceutical company focused on prevention of respiratory infections. Its lead compound, PrEP-001, is a nasally administered, broad-spectrum agent that leverages the innate immune system to prevent upper respiratory tract viral infections. A human proof-of-concept trial for PrEP-001 has been completed, and the company plans to complete ongoing phase 2a development with the new funding. The company develops and will market infectious disease products based on intellectual property licensed from Janssen Sciences Ireland. PrEP Biopharm was co-founded by CEO Ryan Muldoon and CSO Dr. Bruce Malcolm, PhD. The funds from the financing will be used to advance clinical development of its pipeline product.
Team
No current team members are available.